39 results
8-K
EX-99.1
TRML
Tourmaline Bio Inc
13 May 24
Tourmaline Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights
7:15am
in the regulatory environment; the uncertainties and timing of the regulatory approval process; unexpected litigation or other disputes; the impacts
8-K
EX-99.1
TRML
Tourmaline Bio Inc
19 Mar 24
Tourmaline Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
7:09am
financing; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval
8-K
EX-1.1
8hq50gvs7 tiiuglshhp
26 Jan 24
Other Events
4:12pm
424B5
h2dddgg ye
26 Jan 24
Prospectus supplement for primary offering
4:08pm
424B5
stzp oknwof68j1f
24 Jan 24
Prospectus supplement for primary offering
9:20pm
8-K
EX-99.1
duk8 1gvrdccb
24 Jan 24
Results of Operations and Financial Condition
5:10pm
8-K
EX-99.1
7w7wjda s1
8 Jan 24
Regulation FD Disclosure
9:19am
8-K
EX-99.1
fypzlm7bz6n dur
14 Dec 23
Tourmaline Bio Appoints Dr. Clay Siegall as Chairman of the Board
8:27am
424B3
dkofrorqw tweuqxpod
15 Sep 23
Prospectus supplement
6:31am
S-4/A
vfhzhh
25 Aug 23
Registration of securities issued in business combination transactions (amended)
4:34pm
S-4
jklu5cx
19 Jul 23
Registration of securities issued in business combination transactions
7:57pm
425
abgmzvlcybej
22 Jun 23
Business combination disclosure
9:12am
8-K
EX-2.1
zg3tjn3 cn
22 Jun 23
Talaris Therapeutics and Tourmaline Bio Announce Merger Agreement
9:10am